FDA panel votes to keep boxed warning on Chantix

Published



WASHINGTON (AP) — Federal health advisers say a bold-letter warning about suicide risks with Pfizer’s Chantix should remain on the anti-smoking drug until it can reevaluated based on new, rigorous study information.

Eleven advisers to the Food and Drug Administration voted to retain the so-called black box warning about reports of suicide, hostility and depression among Chantix patients. Six advisers said the label should be slightly changed and one panel member voted to remove the warning completely.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.